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Abstract
Background: 2-Methoxyestradiol has been shown to induce both autophagy and apoptosis in various carcinogenic
cell lines. Although a promising anti-cancer agent, it has poor bioavailability and rapid in vivo metabolism which
decreases its efficiency. In order to improve 2-methoxyestradiol’s anti-proliferative properties, a novel 2-
methoxyestradiol analogue, 2-ethyl-3-O-sulphamoyl-estra-1,3,5 (10)16-tetraene (ESE-16), was previously in silico-
designed in our laboratory. This study investigated ESE-16 for its anti-proliferative potential on a cervical
adenocarcinoma cell (HeLa) cell line. Additionally, the possible intracellular crosstalk mechanisms between the two
types of cell death were investigated.
Methods and results: HeLa cells exposed to 0.5 μM ESE-16 for 24 hours showed morphological evidence of both
apoptotic and autophagic death pathways as assessed by polarization-optical transmitted light differential
interference contrast microscopy, fluorescent microscopy and transmission electron microscopy. Flow cytometric
cyclin B1 quantification revealed induction of programmed cell death after halting cell cycle progression in
metaphase. Confocal microscopy demonstrated that ESE-16 caused microtubule fragmentation. Flow cytometric
analysis of cell cycle progression and phosphatidylserine flip determination confirmed induction of apoptosis.
Moreover, an increase in aggresome formation and microtubule-associated protein light chain, LC3, was
demonstrated indicative of autophagy. Both caspase 8 and 3 were upregulated in a spectrophotometric analysis,
indicating the involvement of the extrinsic pathway of apoptotic induction.
Conclusions: We conclude that the novel in silico-designed compound, ESE-16, exerts its anti-proliferative effect on
the tumorigenic human epithelial cervical (HeLa) cells by sequentially targeting microtubule integrity, resulting in a
metaphase block, causing induction of both autophagic and apoptotic cell death via a crosstalk mechanism that
involves the extrinsic pathway. Future investigations will expand on signal transduction pathways involved in both
apoptosis and autophagy for assessment of ESE-16 effects on microtubule dynamic instability parameters.
Keywords: 2-methoxyestradiol, ESE-16, Analogue, Apoptosis, Autophagy, Caspase, Crosstalk, Mitotic block,
Microtubules, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene
Background
Registered as Panzem® by Entremed, Inc (Rockville, MD),
2-methoxyestradiol (2-ME) (Figure 1a), an endogenous
metabolite of 17β-estradiol resulting from sequential
hepatic hydroxylation and methylation by cytochrome P450
enzymes and catechol-O-methyltransferase respectively,
has undergone phase II clinical trials [1-3]. 2-ME induces
apoptosis in endothelial cells, as well as cancer cells
by the intrinsic and extrinsic pathways by both
caspase dependent and -independent pathways [2,4-6].
Not only has 2-ME proven effective in primary treatment
settings, but it has also demonstrated the capability to
sensitize therapy-resistant neoplastic cell types to conven-
tional anti-cancer treatments including radiation therapy
[7,8]. For this reason 2-ME seemed to be a promising
anti-cancer agent, especially in the light of findings that
non-neoplastic cell lines were less affected than cancer cell
lines by exposure to the compound [9].
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Pharmacodynamics of 2-ME appeared to be desirable in
the treatment of neoplasms, but the pharmacokinetic
picture proved problematic. 2-ME has a short half-life and
a poor bioavailability. Being a target for 17β-hydroxysteroid
dehydrogenase-mediated metabolism [10-13], 2-ME is
metabolized with conjunction at the 3 and 17 positions,
together with oxidation at the 17 position [10]. Strategies
have been considered to overcome this rapid biodegrad-
ation and to improve its bioavailability. These strategies
include the design of nanocrystal dispersion techniques
(such as Panzem NCDTM) [3], finding new methods of
delivery such as encapsulation [14] and the design of
2-ME analogues [15-20].
The design of 2-ME analogues aimed to enhance
the already present anti-mitotic and anti-angiogenic
properties of 2-ME itself [20,21]. Dehydration at the
metabolically active 17 position allowed retention of
cytotoxic and anti-tubulin characteristics together
with a decreased metabolic breakdown [22,23]. When
combined with a substitution at position 3 to increase
potency, 3-carboxyamide-2-methoxyestra-1,3,5 (10)16-
tetraene demonstrated suitable anti-mitotic and anti-
microtubule properties with an improved pharmacoki-
netic profile in vitro and in vivo [22].
Sulphamate substitutions on estrogen molecule ana-
logues increase the estrogenic bioavailability due to avoid-
ance of the first hepatic bypass metabolism [24]. This is
attributed to the sulpha moieties’ ability to reversibly bind
to carbonic anhydrase II (CAII) in erythrocytes, followed
by a slow release into the plasma [24,25]. CAIX is over-
expressed in the immediate tumor environment giving
neoplastic cells a growth advantage in their acidic and
hypoxic extracellular milieu [26,27]. CAs also promote
extracellular acidic activation of the metalloproteinases
thereby enhancing the neoplastic cell invasiveness [28].
Therefore selective inhibition of CAIX provides a promis-
ing mechanism to manipulate the extracellular tumor
milieu and to curtail metastatic tendencies [27].
2-Methoxyestradiol-3,17-O,O-bis-sulfamate (2-MEbis
MATE) is a 2-ME analogue, which, by adding a sulpha
moiety at position 3, fulfills two objectives: increasing
the anti-mitotic and spindle disruption capacities
(position 3 modification) and increasing the bioavailability
with the sulpha group [11,29-32]. Literature reported a
more potent anti-mitotic (10-fold), anti-spindle and
anti-angiogenic (60-fold) effect of 2-MEbisMATE when
compared to 2-ME in vitro and in vivo [11,29,32].
Although 2-MEbisMATE has a positive profile of anti-
cancer and anti-angiogenic activities, potency and specifi-
city in CAIX binding needed to be improved. Stander et al.
designed a range of 3 sulphamoylated 2-ME analogues in
silico by modifying the 2- and 17 positions with moieties
known to improve the anti-mitotic activity and to increase
the compounds’ half-life [33]. The designed compounds
were analyzed using a molecular modeling simulation and
docking software, namely AutoDockTools4, to determine
the best binders to the tubulin colchicine binding site and
to CAIX [33].
2-Ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-
16) (Figure 1b) is one of the novel in silico-designed
sulphamoylated 2-ME analogues that needs still to be fully
investigated for its potential anti-proliferative characteris-
tics. ESE-16 is not currently commercially available. In silico
modeling analysis indicated a significant preference of
CAIX over CAII binding, presenting a method to deliver
the drug more specifically to acidic tumor environments.
Our laboratory has established the anti-proliferative action
of ESE-16 at nanomolar concentrations in cell lines
including MCF-7 breast cancer cells (estrogen-receptor
positive), metastatic MDA-MB-231 breast cancer cells,
non-tumorigenic MCF-12A breast cells and SNO non-
keratinizing squamous epithelium cancer [33].
This study aimed to determine whether the novel in
silico-designed 2ME analogue, ESE-16, retained the
previously described anti-proliferative properties of
the parent compound in vitro. Since the compound
Figure 1 Structure of 2-ME and ESE-16. (a) shows the parent compound, (17 beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diol (2-methoxyestradiol).
(b) indicates the substitutions at position 2, 3 and 17 of 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16), a sulphamoylated 2-ME analogue [33].
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was designed to bind to the colchicine site of the
microtubules, the effect of ESE-16 on the spindle
integrity was determined. Effect of this spindle disruption
on cell cycle progression and resultant induction of
programmed cell death pathways were investigated.
Results
Cell cycle
Flow cytometry was used to determine the effect of
ESE-16 on the progression of exposed cells through
the cell cycle, thus indicating an influence on cell viability.
Results were calculated as percentage cells in each
stage of the cell cycle. Cell cycle distribution of the cells
propagated in growth medium (negative control) revealed
an average of 50.82 ± 2.36% in the G1 phase, 21.41 ± 1.85%
in the S phase and 21.73 ± 2.61% in the G2/M phase
(Figure 2ia). Only 0.55 ± 0.19% of the cells were present in
sub-G1 population. There was no statistically significant
difference between cells propagated in growth medium
(negative control) and the DMSO vehicle control sample,
both representing a cell population in logarithmic growth
(Figure 2ib). Cell cycle distribution changed significantly
with actinomycin D- and ESE-16 exposure. A statistically
significant increase of cells in sub-G1 was demonstrated
in the actinomycin D sample (4.93 ± 2.7%, P = 0.04)
(Figure 2ic) and the ESE-16-treated cells (27.93 ± 3.86%,
Figure 2 Cell cycle analysis after 24 hour exposure to ESE-16. (2i) Histograms derived from flow cytometry comparing cell distribution
within the cell cycle between control samples and ESE-16 treated cells. (2ia) Cell cycle distribution of cells grown in medium only. (2ib) Cells
exposed to DMSO as a vehicle control. (2ic) Cells exposed to actinomycin D as a positive apoptosis control. (2id) Cells exposed to ESE-16
demonstrating an increase in G2/M and sub-G1 populations with a concurrent decrease in G1- and S phase. (2ii) Graphical representation of the
histogram results. (* indicates a statistically significant difference when compared to DMSO vehicle control samples with a P value of < 0.05).
Standard deviation is indicated by T-bars.
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P = 0.0002) (Figure 2id). G1 populations were significantly
decreased, to 37.29 ± 5.08% (P = 0.028) and 10.16 ± 3.79%
(P = 0.0007) of the cell population in actinomycin D- and
ESE-16-treated cells respectively. ESE-16 showed a decrease
in viable cells (G1- and S phases) and a distinct increase of
cells in G2/M phase (51.28 ± 7.09%, P = 0.0034). Figure 2ii
summarizes the flow cytometric data of the cell cycle
comparing the distribution of cells within the cell cycle
in the various samples.
Apoptosis studies
In order to detect and to discriminate between the
induction of apoptosis, necrosis and viable cells, flow
cytometric analysis using labeled annexin antibodies for the
detection of phosphatidylserine flip in ESE-16-exposed cell
membranes was done. Analysis of the data generated from
dot plots (Figure 3i) via Cyflogic version 1.2.1 software
revealed that in a healthy cell population (DMSO as a
vehicle control), 92.8 ± 1.84% of the cells were viable,
with 7.02 ± 1.83% undergoing apoptosis and an insignificant
0.16 ± 0.02% in necrosis. There were satistically insignificant
differences between cells propagated in growth medium
and DSMO vehicle controls. Actinomycin D induced apop-
tosis (21.28 ± 1.76%, P = 0.0006), with a significant decrease
of viable cells (77.68 ± 1.89%, P = 0.0005). A decrease
in cell viability was demonstrated in the ESE-16-exposed
cells (64.22 ± 4.67%, P = 0.0006), with a corresponding rise
in apoptotic cell numbers (27.32 ± 2.67%, P = 0.0004).
There was no significant difference in the proportion of
necrotic cells between the samples (P = 0.08). Results are
summarized graphically in Figure 3ii.
Cyclin B1 detection
A cyclin B1-phycoerythrin conjugated antibody (Milli-
Mark™ Anti-Cyclin B1-PE, clone GNS3 (8A5D12))
was used to quantify cyclin B1 protein up-regulation
in ESE-16-treated HeLa cells by employing flow
cytometric analyses. This was conducted to deter-
mine the compound’s ability to induce a metaphase
block. Figure 4i displays representative scatter plots,
with the fluorescent intensity of the PE-conjugated
cyclin B1 antibody plotted against forward scatter as
a determinant of cells size (Figure 4ia and ib) and
side scatter indicative of cell complexity (Figure 4ic
and id). Scatter plots displayed a higher fluorescent
signal in more complex and smaller sized cells which
are representative of cells in metaphase [34,35].
Figure 4ii shows the intensity histogram, demonstrat-
ing an increased intensity and a right shift of the
ESE-16-exposed cells. A 2.47 ± 0.49-fold increase of
cyclin B1 expression (P < 0.05) in the ESE-16-exposed
cells was revealed when compared to the DMSO
vehicle control.
Aggresome detection: Autophagy
In order to evaluate the induction of autophagy in ESE-
16-treated cells, flow cytometric quantification of aggresome
formation was conducted. Using the formula provide
in the manufacturer’s protocol, the aggresome activity
factor (AAF) was calculated. According to the manafacture’s
protocol, an AAF of more than 25 is regarded as a statisti-
cally significant increase in aggresome formation. There
was no statistically significant difference between cells
propagated in growth medium and DMSO vehicle
control samples. Figure 5 is a graphic representation
of the AAF of tamoxifen- and ESE-16-treated cells,
calculated at 44.3 ± 6.36 and 40.7 ± 0.53 repectively.
Data indicate that ESE-16 induces aggressome formation,
indicative of autophagy.
Autophagy-related protein LC3 B determination
Flow cytometric analysis of autophagy-related protein
LC3 B expression was done to quantify the formation of
autosomal vacuoles in ESE-16-eposed HeLa cells. The
MAP1LC3 B rabbit antibody (Biosensis, Thebarton,
Australia) was utilized and the FL1 fluorescence of at
least 10 000 cells were analyzed per repeat. There
was a statistically significant increase of LC3 B within
the tamoxifen (x mean FL1 = 106.5 ± 11.6; P = 0.041)
and ESE-16-exposed cells (x mean FL1 = 81.2 ± 4.08;
P = 0.040) when compared to the DMSO vehicle control
(x mean FL1 = 66.6 ± 0.82) (Figure 6).
Signal transduction: quantification of caspases 8 and 3
The FLICE/Caspase 8 colorimetric kit was used to deter-
mine caspase 8 activation in cell lysates of the ESE-16
exposed HeLa cells and of the relevant controls. There was
no statistically significant difference noted between readings
of cells propagated in growth medium only, DMSO vehicle
and actinomycin D controls. A 1.9 ± 0.4-fold increase in
caspase 8 induction in the ESE-16-exposed HeLa cells was
observed when compared to the baseline (P-value 0.04)
(Figure 7). Caspase 3 activity in cell lysates was measured
using the BioVision Caspase-3/CPP32 Colorimetric Assay
Kit. Cells propagated in growth medium and DMSO
vehicle controls showed no statistical difference between
these results. A statistically significant up-regulation
of caspase 3 activity in the actinomycin D positive
control (3.75 ± 0.21-fold increase, P = 0.011) was noted
and a pronounced increase in the ESE-16-treated cells
(8.03 ± 0.21-fold increase, P = 0.008) (Figure 7).
Polarization-optical transmitted light differential
interference contrast microscopy (PlasDIC)
To substantiate flow cytometric data and to evaluate
ESE-16’s anti-proliferative effects, PlasDIC microscopy
was used. Cells exposed to DMSO as a vehicle control
(v/v%) (Figure 8a) continued to grow in a logarithmic
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manner resulting in confluent cells in various stages of
mitosis (mostly interphase). Cells treated with tamoxifen
revealed increased presence of vacuolar structures (most
likely to be autophagosomes) and cells in distress (cell
protrusions) (Figure 8b). Cells exposed to actinomycin D
revealed apoptotic bodies, multiple shrunken cells, ghost
Figure 3 Analysis of HeLa cell viability after 24 hour ESE-16 exposure. Apoptosis was determined by flow cytometric quantification of
phosphatidylserine-flip. (3i) Dots plots of HeLa cells after 24 hour exposure to growth medium (3ia), DMSO vehicle control (3ib), actinomycin D
positive apoptosis control (3ic) and ESE-15 (3id). A statistically significant decrease of viable cells was seen in actinomycin D- and ESE-16-exposed
cells with a concurrent increase of apoptotic cells. There were no statistically significant differences observed between cells propagated in growth
medium only and DMSO vehicle controls in any of the cell cycle categories. No significant difference was calculated in the amount of necrotic
cells in all samples. (3ii) Graphical representation of the dot plot data (* P < 0.05, standard deviation represented by T-bars).
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cells and scattered cell debris (Figure 8c). Shrunken and
round cells in metaphase block, the formation of apop-
totic bodies, as well as evidence of cell debris were vis-
ible in the ESE-16-treated HeLa cells (Figure 8d). All
treated samples displayed a decrease in cell density.
Fluorescent microscopy
In order to substantiate autophagy induction, a fluores-
cent microscopic technique using monodansylcadaverine
(MDC) was employed as described by Laane et al. [36].
Figure 9a is a representative image of HeLa cells exposed
to DMSO as a vehicle control which displayed confluent
growth and non-specific MDC staining. Cells exposed to
tamoxifen as the positive autophagy control demonstrated
the formation of MDC-positive vacuoles (Figure 9b), as
did the ESE-16-exposed cells (Figure 9c). A UV filter with
excitation 380 nm and emission 420 nm was used for
MDC staining detection.
Transmission electron microscopy
TEM was used to analyze detailed intracellular and
membrane properties of HeLa cells exposed to ESE-16
in order to demonstrate morphological evidence of
autophagic and apoptotic cell death, both of which were
Figure 4 Flow cytometric evaluation of cyclin B1 up-regulation in HeLa cells. (4i) Dot plots of ESE-16 exposed cells (b and d) were
compared to the DMSO vehicle control (a and c). FL3 log fluoresce intensity was plotted against cell size determined by forward scatter (a and b)
and cell complexity as established with side scatter (c and d). An increase in expression of cyclin B1 in the ESE-16-treated cells was observed in the
smaller (b) and more complex (d) cells. (4ii) Intensity histogram of cyclin B1 expression within the DMSO vehicle control (black) and ESE-16-exposed
cells (blue) demonstrating an increase in intensity and a right shift in the drug-exposed cells.
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hypothesized to be caused by ESE-16. Figure 10ai
demonstrates the smooth cell membrane with normal cell
protrusions (Figure 10aii) of cells exposed to the DMSO
vehicle control. Comparative cellular morphology to cells
propagated in growth medium was observed (not shown).
Intracellular organelles including mitochondria, nucleoli
and nuclear membranes are clearly identifiable, with
no vacuolar formation. In contrast, cells exposed to
the positive control agents, tamoxifen and actinomycin D,
displayed characteristics of cellular distress and pro-
cesses of autophagy and apoptosis respectively. Figure 10bi
shows the marked increase of vacuolar structures in
response to tamoxifen exposure. These vacuolar structures
were most likely autophagosomes in the light of increased
LC3 B expression observed as determined by flow
cytometry. The latter observation was further sup-
ported by an increase in aggresomes demonstrated via
a significant AAF value. Cells are smaller in size, and
the nuclear membrane, nucleolus and cell membrane
are still intact. Figure 10bii shows one of the vacuolar
structures (most likely an autophagosome), demon-
strating the engulfed cellular contents and organelles
within a membrane. Actinomycin D treatment had a
pronounced effect on cell membrane structure, with
an increase of membrane protrusions (Figure 10ci and cii).
Additionally, signs of apoptosis are evident and include
pyknosis, karyorhexis and the presence of apoptotic
bodies. Figure 10d demonstrates the effect that ESE-
16 exposure has on HeLa cells. A significantly dis-
tressed cell (representative image of cells treated with
ESE-16) in the process of undergoing both apoptosis
and autophagy is depicted (Figure 10di). Combination of
cell death types I and II are represented by the characteris-
tic apoptotic body formation, chromatin hypercondensation
and an increased number of cell membrane protrusions of
the former and the presence of numerous vacuolar
structures (most likely autophagosomes) as part of the
latter. The nuclear membrane is absent. Vacuolar
structures and organelles such as Golgi bodies were
identified (Figure 10dii).
Confocal microscopy
In order to observe the effects of ESE-16 on HeLa cell
cytoskeletal microtubule architecture, confocal micros-
copy was used to visualize α-tubulin. Figure 11a is a rep-
resentative image of HeLa cells exposed to the DMSO
vehicle control. Confluency of cell growth in various
stages of mitosis (mostly interphase) was demonstrated
with organized spindle formation visible within these cells.
A cell undergoing telophase is shown in Figure 11aii with
the chromatids being separated by an organised and func-
tional spindle formation. Cells were exposed to 2-ME as a
positive control for spindle depolymerization. Figure 11bi
and Figure 5bii demonstrate cells in metaphase block and
disorganized tubulin structure after 2-ME exposure with a
decrease in cell density. Figure 11c depicts the effect that
ESE-16 exposure has on the HeLa cell microskeleton.
Total disintegration of the tubulin network is visible in
Figure 11ci and cii. Additional evidence of apoptosis was
identified in these cells and included margination of DNA,
a decrease in cell density and apoptotic body formation.
Discussion
In order to combine and enhance the anti-cancer
characteristics of 2-ME with the advantages gained by
strategic modification previously mentioned, ESE-16
was in silico-designed. Dose-dependent studies over a
24-hour period were conducted in our laboratory and
Figure 5 Aggresome activity factor in ESE-16-exposed HeLa cells. Cells treated with tamoxifen and ESE-16 was compared to the negative
DMSO vehicle control. Standard deviations are annotated with T-bars. An AAF > 25 represents a significant increase in intracellular aggresome
formation, strongly indicative of autophagy (standard deviation represented by T-bars).
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an IC50 of 0.5 μM on HeLa cervical adenocarcinoma
cells using the crystal violet staining method was
established (data not shown). This showed an increased
potency when compared to 2-ME, which decreased HeLa
cell numbers to 60% after exposure to 1 μM 2-ME for
72 hours [37,38]. The mechanisms of cell death induced
by ESE-16 were further investigated in this study.
Confocal images obtained where HeLa cells were
exposed to 0.5 μM ESE-16 for 24 hours and stained with
anti-tubulin α antibodies revealed disintegration of tubu-
lin structure, supporting the previous report of micro-
tubule abrogation in MDA-MB-231 cells [33]. These
results confirmed ESE-16 as a spindle poison, resulting
in the G2/M block. Light microscopic morphological
changes also revealed a marked decrease in cell density,
with the remaining cells being mostly shrunken and
rounded. Cellular debris was evident, as well as the pres-
ence of apoptotic bodies. Fluorescent- and transmission
electron microscopy corroborated characteristics of both
apoptosis and autophagy.
Cell cycle progression analysis by flow cytometry of
ESE-16-exposed HeLa cells demonstrated a metaphase
block. Loss of cell membrane asymmetry occurring with
the translocation of phosphatidylserine to the outside of
the cell during apoptosis induction (PS-flip) was also
quantified with flow cytometry. ESE-16-exposed HeLa
cells demonstrated a decrease in cell viability to 64.22%,
with a concomitant increase in the number of cells in
Figure 6 Autophagy-related protein LC3 B determination in ESE-16-exposed HeLa cells. (a) Overlay histogram of LC3 B expression in HeLa
cells exposed to the DMSO vehicle control (yellow), tamoxifen (blue) and ESE-16 (black), demonstrating a right shift in the treated samples.
(b) Graphic representation of the increase in LC3 B fluorescence between the DMSO vehicle control and ESE-16-exposed HeLa cells (* P < 0.05,
standard deviation represented by T-bars).
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apoptosis (27.32%). Results confirmed prior data from our
laboratory that (200 nM) ESE-16-exposed MDA-MB-231
cells showed a G2/M block after 24 hours, as well as an
increase in the sub-G1 fraction, whereas after 48 hours
nearly all the cells were present be in the sub-G1
fraction [33].
The induction of mitotic block followed by apoptosis
(and autophagy) in MCF-7 cells exposed to 1 μM 2-ME
for 24 hours has previously been published by our
laboratory [6]. Gene expression microarrays showed
differential expression of genes mapped to a variety of
processes involved in managing the cell in metaphase
block and subsequent programmed death induction
(including genes involved in microtubule dynamics, cell
cycle checkpoints, cyclin B1 degradation, autophagy and
apoptotic regulation) [6].
In the light of the mitotic block demonstrated in HeLa
cells exposed to 0.5 μM ESE-16 for 24 hours by morpho-
logical studies and flow cytometric analysis, levels of cyclin
B1 were determined using flow cytometry. An overall 2.47-
fold increase of cyclin B1 was determined when compared
to the vehicle control. A higher fluorescent signal was
emitted from the smaller more complex cells (representing
cells in metaphase block) when fluorescence against side-
and forward scatter was plotted. Up-regulation of cyclin B1
expression corroborated the finding of the cell cycle ana-
lysis, in which there was a significant increase in cells in
metaphase after ESE-16 exposure. Formation of tetrapoidic
cells after mitotic spindle inhibition may have caused
forced overexpression of cyclin B1, as well as showing a
role of this molecule in cell size determination [34,39].
The fate of a cell in unmitigated mitotic arrest seems to
depend on the interplay between cyclin B and MCL1
levels [40]. Both MCL1 and cyclin B are at peak concen-
trations just after spindle poisons have induced the mitotic
block: the former to apprehend the onset of apoptosis
while cellular restoration is being attempted, and the
latter due to the SAC-induced arrest of cell cycle progres-
sion due to unattached kinetochores [41]. A rapid up-
regulation of cyclin B1 was demonstrated by Newman et al.
in MCF-7 cells on exposure to 500 nM taxol, 2-ME and 2-
MEbisMATE after 24 hours [42]. The increase in cyclin B
blocks the progression of the cell cycle and apoptosis until
it is degraded, at which point the cell is able to resume its
cycle or undergo apoptosis. After 48 hours, the levels of
cyclin B deteriorated in the exposed MCF-7 cells, allowing
the cells to undergo apoptosis via p53 induction (2-ME did
not induce p53 at that concentration) [42]. Additionally,
the anti-apoptotic BCL2 protein had been deactivated by
phosphorylation in the 2-MEbisMATE and taxol-treated
MCF-7 cells after 24 hours of exposure [42].
ESE-16 causes a disrupted spindle assembly and may
activate the spindle assembly checkpoint (SAC) resulting
in mitotic block and inducing apoptosis [43]. Increased
cyclin B1 levels may also be due to ESE-16 blocking the
mitotic escape routes downstream of the checkpoint which
prevents the premature exit of cells from the induced
apoptosis pathways, thereby preventing resistance to the
compound’s effects and increasing its anti-tumorigenic
properties. The latter serves to slow down proteolytic
breakdown of cyclin B1, allowing an increased opportunity
for death initiation [43].
2-ME has been implicated in induction of the extrinsic
apoptotic pathway in several cell lines [44]. Both caspase
8 and 3 were up-regulated after a 24 hour exposure of
HeLa cells to 0.5 μM ESE-16 in this study. Since caspase 3
Figure 7 Fold increase in caspase 8 and 3 activity in ESE-16-treated cells. Compound treated cells were compared to cells propagated in
growth medium (MO), the DMSO vehicle and actinomycin D controls (* P < 0.05, standard deviation represented by T-bars).
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is an executioner caspase common to both intrinsic and
extrinsic pathways, the deduction that ESE-16 induces a
caspase-dependent mode of cell death can be made.
Induction of the intrinsic apoptotic pathway with the
release of cytochrome c causes the formation of the active
apoptosome, resulting in the activation of caspase 9, which
in turn cleaves the downstream executioner caspases 3, 6
and /or 7 [45]. Mitochondrial membrane potential is
affected in ESE-16-exposed HeLa cells indicates involve-
ment of the intrinsic apoptotic pathway. The latter was
substantiated by the demonstration of caspase 6 activ-
ity [18]. The increase in caspase 8 activity in this
study indicates the possibility of an extrinsic pathway
concomitantly with the intrinsic pathway.
Evidence of autophagy occurring simultaneously to
apoptosis in HeLa cells exposed to 0.5 μM ESE-16 was
indicated via MDC fluorescent microscopy and TEM
analysis. In order to support these findings, the AAF was
calculated in a flow cytometric assay based on the principle
that misfolded proteins are relegated to aggresomes which
Figure 9 MDC fluorescence microscopy of ESE-16-exposed HeLa cells. (a) DMSO (vehicle control) demonstrated dividing cells with
satisfactory confluency and non-specific MDC staining. (b) Tamoxifen-exposed cells demonstrating MDC-stained vacuoles. (c) ESE-16-exposed
cells demonstrated a compromised cell density and the formation of MDC-stained vacuoles.
Figure 8 PlasDIC micrographs of HeLa cells after a 24 hour exposure. (a) DMSO (vehicle control) exposure demonstrated confluent growth
of HeLa cells. Cells were mostly in interphase. (b) Tamoxifen exposure (positive autophagy control) demonstrated a reduction in cell density and
an increase in vacuolar structures and cell protrusions (cell distress). (c) Actinomycin D exposure (positive apoptosis control) resulted in a
reduction in cell density, apoptotic bodies, shrunken cells, ghost cells and cellular debris. (d) HeLa cells exposed to 0.5 μM ESE-16, demonstrating
the hallmarks of metaphase block and apoptosis. (Arrow colour key: orange = nucleoli; blue = vacuolar structures; yellow = rounded cells in
metaphase; red = cell protrusion; white = apoptotic bodies).
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Figure 10 (See legend on next page.)
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are cleared by autophagy. Additionally, the quantification
of autophagy-related protein LC3 B was done in ESE-16
exposed HeLa cells. LC3 B is required for the formation of
autophagosomes [46]. Results demonstrated an increase in
the AAF, as well as LC3 B expression in ESE-16-treated
cells, thus indicating that autophagy is induced along
with apoptosis.
Caspases and Beclin-1 may mediate cross talk between
apoptosis and autophagy [47]. When Beclin-1, a B-cell
lymphoma 2 (BCL2) homology domain 3 (BH3) family
member is bound to BCL2 or BCL-extra long (BCL-XL), its
interaction with phosphatidylinositol 3-kinase Catalytic
Subunit Type 3 (PI3KC3) along with other proteins which
are core to the autophagy-inducing complex, is inhibited,
thereby preventing autophagy [48,49]. However, Beclin-1
and PI3KC3 are direct substrates of caspases (3, 7 and 8), a
process which may be observed during induction of
both the intrinsic and extrinsic apoptotic pathway
[50]. BCL-2–associated X protein (BAX) over-expression,
which induces the intrinsic apoptotic pathway has been
shown to cause caspase cleavage of Beclin-1, as does acti-
vation of tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) [51,52]. Once cleaved, the
Beclin-1 C-terminal acquires a new apoptotic-promoting
function [50]. Autophagy-related protein 4D (Atg4D)
cleavage by caspase 3 induces autophagy activity, but has a
cytotoxic effect which amplifies apoptosis via the intrinsic
mitochondrial pathway [53]. Thus it can be proposed that
caspase cleavage of Beclin-1 and Atg4D can prevent pro-
tective autophagic induction and the C-fragment of Beclin-
1 can sensitize cells to pro-apoptotic signals [47]. Crosstalk
between autophagy and apoptosis in HeLa cells induced by
ESE-16 destruction of microtubule integrity and resultant
metaphase block, involves the extrinsic pathway with
increased caspase 8 and 3 activity.
Conclusion
Data from this in vitro study supports the concept
that the novel in silico-designed estradiol analogue,
ESE-16, may act as a potential anti-cancer drug.
ESE-16 induced both autophagy and apoptosis in cer-
vical adenocarcinoma (HeLa) cells in response to a
persistent mitotic block caused by microtubule
abrogation. An increase in caspases 8 and 3 impli-
cated the extrinsic pathway of induction. The in-
volvement of Beclin-1 as a mediator between
autophagy and apoptotis in ESE-16 exposed cells must
be established. Future in vivo studies will determine
whether this novel anti-neoplastic drug exerts any sig-
nificant side-effects and whether the in silico-design
of our laboratory to increase the compounds’ bioavail-
ability was successful.
Materials and methods
Reagents
Dulbecco’s Modified Eagle Medium (DMEM) was pur-
chased from Separations (Johannesburg, South Africa).
European-grade heat-inactivated fetal calf serum (FCS)
and RNase A were obtained from BIOCOM biotech (Pty)
Ltd. (Clubview, South Africa). Syringe filters (0.22 μm),
sterile cell culture flasks and plates were obtained
through Sterilab Services (Kempton Park, Johannesburg,
South Africa). Penicillin, streptomycin and fungizone
were purchased from Highveld Biological (Pty) Ltd.
(Sandringham, South Africa), as was the trypsin/versene.
Triton X-100, 100% ethanol, and propidium iodide were
purchased from Sigma-Aldrich (St. Louis, Missouri, United
States of America (USA). All additional chemicals were of
analytical grade and were purchased from Sigma-Aldrich
(St Louis, Missouri, USA).
Chemical compound and appropriate controls
The non-commercially available 2-ethyl-3-O-sulphamoyl-
estra-1,3,5(10)16-tetraene (ESE-16) was synthesized by
iThemba (PTY) Ltd. Pharmaceuticals (Modderfontein,
Gauteng, South Africa). The IC50 of ESE-16 in HeLa cells
was established to be 0.5 μM via a crystal violet staining
technique in a dose-dependent study (data shown in
Additional file 1). As a negative vehicle control,
medium of the cell samples were supplemented with
an equal concentration of dimethyl sulphoxide (DMSO).
The DMSO content of the final dilutions never exceeded
0.1% (v/v). Positive controls constituted actinomycin
D at a final concentration of 0.1 μg/ml for apoptosis,
20 μM tamoxifen for autophagy and 1 μM 2-ME for
(See figure on previous page.)
Figure 10 Transmission electron microscopy of exposed HeLa cells. (ai) HeLa cell exposed to the DMSO vehicle control which demonstrated a
smooth well-defined cell membrane with normal cell protrusions, as well as an intact nuclear membrane. Organelles such as mitochondria are
identifiable (scale bar: 10 μm). (aii) Representative image of the cell membrane showing normal cellular protrusions (scale bar: 2 μm). (bi) HeLa cell
after exposure to tamoxifen (positive autophagy control). Cells displayed vacuolar structures, although the cell membrane, nucleolus and nuclear
membrane remained intact. (bii) Representative image of a vacuolar structure (scale bars represent 5 μm in (bi) and 0.5 μm in (bii)). Figure (ci) and
(cii) are representative images of actinomycin D-exposed cells showing apoptotic bodies, pyknosis and an increase in the number of cellular
membrane protrusions. The nuclear membrane is absent (scale bars: 5 μm in (ci) and 2 μm in (cii)). Images (di) and (dii) of ESE-16-treated cells
showed the presence of vacuolar structures (similar to the tamoxifen control), apoptotic bodies, nuclear condensation, increased membrane
protrusions and absence of the nuclear membrane demonstrating a cell in distress (scale bars: 5 μm (di) and 2 μm (dii) respectively). (Arrow colour
key: orange = nucleoli; red = nuclear membrane; blue = vacuolar structures; yellow = pyknosis; white = apoptotic bodies).
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microtubule depolymerization (Sigma-Aldrich, St Louis,
Missouri, USA).
Cell line and cell culture
The commercially available tumorigenic human epi-
thelial cervical cell line, namely the HeLa cell line,
was acquired from Highveld Biological (Pty) Ltd
(Sandringham, Johannesburg, South Africa). HeLa
cells were propagated and maintained in 25 cm2 or
75 cm2 tissue culture flasks in a humidified atmosphere at
37°C, 5% CO2 in a Forma Scientific water-jacketed incuba-
tor (Ohio, USA). HeLa cells were cultured in DMEM
supplemented with 10% heat-inactivated FCS (56°C, 30 mi-
nutes) for optimal cell growth. 100 U/ml penicillin G,
100 μg/ml streptomycin and fungizone (250 μg/L) were
added to the medium for infection control. Experiments
were performed in either six-well plates or 25 cm2 cell cul-
ture flasks. For six-well plates, exponentially growing cells
were seeded at 350 000 cells per well in 3 ml fresh mainten-
ance medium. For 25 cm2 cell culture flasks, exponentially
growing HeLa cells were seeded at 1 X 106 cells per flask to
a final volume of 5 ml of maintenance medium. After
a 24-hour incubation period at 37°C to allow for cell
adherence, cells were exposed to 0.5 μM ESE-16 and
Figure 11 Confocal microscopic immunofluorescent images of the microtubule structure within ESE-16-exposed HeLa cells. Alexa-488
fluorescent labeled tubulin-α antibodies fluoresce green allowing visualization of the tubulin network, while DAPI stained nuclear material blue.
(ai) DMSO exposure (vehicle control) demonstrated cell confluency, various stages of cell division and intact organised tubulin networks as seen
in medium only exposed cells (not shown). (aii) A cell in telophase, demonstrating intact microskeletal structure. (bi) and (bii) HeLa cells exposed
to 2-ME as a positive control for a microtubule depolymerizing agent, demonstrated compromised cell density and cells in metaphase block with
disorganised tubulin structures. (ci) and (cii) 24 Hour ESE-16 exposure showed complete tubulin disintegration together with apoptotic body
formation, DNA margination and a decrease in cell density. (Arrow colour key: orange = nucleoli; yellow = DNA margination; white = apoptotic
bodies; red = microtubules, organized and intact in the DMSO vehicle control, and disintegration in the 2-ME control and ESE-16-treated cells).
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the relevant controls were included. Cells were incu-
bated for a further 24 hours at 37°C as the exposure
time-frame.
Cell cycle analysis
Exposed cells were trypsinized and collected for ana-
lysis. Cells were centrifuged at 150 g and subsequently
resuspended in 200 μl ice-cold PBS containing 0.1%
FCS. Ice-cold 70% ethanol was added in a drop-wise
manner while vortexing gently. Samples were incu-
bated at 4°C for a minimum of 12 hours, after which
the cells were pelleted by centrifugation. Cells were
resuspended in PBS containing propidium iodide
(40 μg/ml), RNase A (100 μg/ml) and Triton X-100
(0.1%) and incubated while protected from light at
37°C for 40 minutes. Analysis entailed measurement
of propidium iodide fluorescence (FL3) on a FC500
system flow cytometer (Beckman Coulter, South Africa
(PTY) Ltd.) equipped with an air-cooled argon laser
excited at 488 nm. Aneuploid and aggregated cells, as well
as cell debris were gated out by visual inspection. Cell cycle
distributions from generated histograms were expressed as
a percentage of cells in each phase.
Apoptosis studies
Analysis was performed using the BioVision Annexin
V-FITC reagent kit acquired from BioVision Research
Products (Mountain view, California, USA. The 1X
binding buffer (supplied in the kit) was prepared as
directed. According to manufacturer’s protocol, 500 000
exposed cells from each flask were washed in PBS,
centrifuged and resuspended in 1X binding buffer. Double
staining was done by adding 1 μl Annexin V-FITC and
1.2 μl 40 μg/ml propidium iodide to the cells, which were
incubated for five minutes at room temperature in the dark.
Annexin V (FL1) and propidium iodide (FL3) fluorescence
were measured in 10 000 cells per sample with a FACS
FC500 System flow cytometer (Beckman Coulter South
Africa (Pty) Ltd.) equipped with an air-cooled argon laser
excited at 488 nm. Results were expressed as a percentage
of cells in three categories namely; viable cells, apoptotic
cells and necrotic cells.
Cyclin B1 detection: metaphase block
Exposed cells were trypsinized, collected, centrifuged
and washed with 1 ml ice-cold PBS. Cells were
resuspended in 200 μl ice-cold PBS containing 0.1%
FCS. Cells were fixed with 10 ml ice-cold 70% ethanol
and stored at 4°C for 24 hours. Cells were centrifuged
and washed twice with PBS to remove the ethanol. A
working antibody solution (Milli-Mark™ Anti-Cyclin B1-PE,
clone GNS3 (8A5D12), Millipore Corporation, Temecula,
California, USA) was prepared by diluting the primary anti-
body in PBS in a 1:5 ratio. A 1:10 antibody solution to 0.1%
Triton X-100 PBS was added per 1 X 106 cell sample. Cells
were incubated in the conjugated cyclin B1 antibody solu-
tion for 40 minutes at 37°C. Cells were washed with PBS.
All procedures after the incubation with the antibody were
conducted in a light protected environment. PE (FL3)
fluorescence was measured with a FC500 System flow
cytometer (Beckman Coulter South Africa (Pty) Ltd.)
equipped with an air-cooled argon laser excited at
488 nm. Aggregated and aneuploid cells were excluded
from the analysis. 10 000 cells were analyzed per sample.
Measurement of PE-conjugated cyclin B1 fluorescence of
control and exposed HeLa cells was done using the
normalized area of the dot-plot.
Autophagy: aggresome detection
The Enzo Life Sciences’ ProteoStat® Aggresome Detection
Kit was purchased from Enzo Life Sciences Inc. (New
York, USA). The kit provided the ProteoStat® Aggresome
Detection Reagent and the 10X assay buffer. Subsequent
to the 24 hour exposure, cells were harvested via
trypsinization and resuspended in 200 μl PBS prior to
adding 4% formaldehyde in a drop-wise manner while
vortexing the tube. Cells were left at room temperature
for 30 minutes. Samples were centrifuged and a PBS
washing step followed. While vortexing, permeabilizing
solution was added in a drop-wise fashion, after which the
sample was incubated for 30 minutes on ice. Cells
were collected by centrifugation, after which they
were washed in PBS. Cells were resuspended diluted
ProteoStat® Aggresome detection reagent. Cells were
incubated at room temperature for 30 minutes in the
dark. Fluorescence within 10 000 cells of each sample
was analyzed in the FL3 channel of the FACS FC500
System flow cytometer (Beckman Coulter, South Africa
(Pty) Ltd.) equipped with an air-cooled argon laser
excited at 488 nm. After obtaining the mean fluorescence
intensity (MFI) for the samples (cells propagated in
medium only as the negative control, ESE-16-treated
cells and a positive autophagy control), the aggresome
activity factor (AAF), as determined according to the
supplier’s manual, was calculated as follows:
AAF ¼ 100 MFIRx MFICONTð Þ=MFIRx
where AAF is the aggresome activity factor; MFIRx is
the mean fluorescence intensity of the treated sample;
and MFICONT is the mean fluorescence intensity of
the control sample. An AAF of more than 25 was in-
dicative of a positive result and a significant increase
in aggresome formation.
Autophagy-related protein LC3 B determination
After a 24 hour exposure to ESE-16 and the relevant
controls, cells were trypsinized and washed with ice-cold
PBS. Cells were fixed with 0.01% paraformaldehyde/PBS
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for 10 min, then pelleted and resuspended in ice-cold
PBS. Cells were permeablized with ice-cold methanol
(−20°C), added in a drop-wise manner. Cells were washed
twice with cold PBS. Pelleted cells were resuspended in
the primary antibody solution (0.5:1000 MAP1LC3 B
rabbit antibody (Biosensis, Thebarton, Australia) to PBS,
1% BSA) and incubated for 2 hours at 4°C protected
from light. Cells were washed thrice with washing
buffer (PBS, 0.05% Triton, 1% BSA). Blue carrier
protein (FL1) fluorescence was measured with a FC500
System flow cytometer (Beckman Coulter SA (Pty) Ltd.)
equipped with an air-cooled argon laser excited at 488 nm.
Data from at least 10 000 cells were analyzed. Measurement
of Blue Carrier Protein-conjugated MAP1LC3 B antibody
fluorescence of control and exposed HeLa cells was done,
using the normalized area of the dot-plot. An overlay histo-
gram was constructed from the dot plots using Cyflogic
version 1.2.1 software (Pertu Therho, Turko, Finland).
Quantification of caspases 8 and 3
The FLICE/Caspase 8 colorimetric kit was used to
determine caspase 8 activation and the BioVision
Caspase-3/CPP32 Colorimetric Assay Kit was used to
quantify caspase 3 activity. Both kits were purchased
from BioVision Research Products (Mountain View,
California, USA). Included were the cell lysis buffer, 2X
reaction buffer, 4 mM IETD-pNA (in the caspase 8 kit),
4 mM DEVD-pNA (in the caspase 3 kit), 1 M dithiothreitol
(DTT) and the dilution buffer. 1–5 × 106 treated cells were
pelleted by centrifugation after trypsinization, and re-
suspended in ice-cold cell lysis buffer and incubated on ice
for 10 minutes. Following centrifugation, the supernatant
was transferred to eppendorf tubes and placed on ice. The
protein concentration was determined using the Pierce®
BCA protein assay kit (Thermo Fisher Scientific Inc.
Rockford, Illinois, USA) as per manufacturers protocol. Pro-
tein (50 μg) of each assay was diluted in 50 μl cell lysis buf-
fer and placed in a 96-well plate, to which an equal volume
of 2× reaction buffer (containing 10 mM DTT) was added.
The reaction was initiated by adding 5 μl DEVD-pNA for
caspase 3 or IETA-pNA for caspase 8. Plates were incubated
for 120 minutes at 37°C, protected from light and the
absorbance was read at 405 mn on the BioTek Epoch
multi-volume spectrophotometer system (BioTek Instru-
ments Inc., Analytical Diagnostic Products, Weltevreden
Park, South Africa). Background readings from the buffers
were first subtracted from the total readings, after which the
fold increase of caspase activity was determined by using
the DMSO vehicle control as the baseline reading.
Polarization-optical transmitted light differential
interference contrast microscopy
Viable cells (3.5 × 105) determined by trypan blue exclu-
sion, were seeded in six-well plates and allowed to attach
for 24 hours. PlasDIC images were obtained using the
Zeiss Axiovert-40 microscope (Göttingen, Germany) and
Zeiss Axiovert MRm monochrome camera (Carl Zeiss
MicroImaging GmbH, Göttingen, Germany) before and
after a 24 hour exposure to vehicle controls, positive
controls or ESE-16 respectively.
Fluorescent microscopy
Fluorescent microscopy using monodansylcadaverine
(MDC) was employed to determine the effect that
ESE-16 has on acidic vesicular organelle formation
[36]. After discarding the growth medium, ESE-16
exposed cells (and relevant controls) were incubated
in 0.05 mM MDC for 10 minutes at 37°C. Cells were
washed four times with PBS. Cells were examined
with a Zeiss inverted Axiovert CFL40 microscope and
Zeiss Axiovert MR monochrome camera (Carl Zeiss
(Pty) Ltd., Johannesburg, South Africa). A UV filter
with excitation 380 nm and emission 420 nm was
used for detection of MDC staining. In order to curtail
fluorescent dye quenching, all procedures were performed
in a dark room.
Transmission electron microscopy
After a 24 hour exposure to ESE-16 and the relative
controls, cells were collected via trypsinization and fixed
in diluted Karnovsky’s fixative (2.5% glutaraldehyde and
2.5% formaldehyde in 0.075 M phosphate buffer at
pH 7.4–7.6) for 45 minutes at room temperature. Cells
were washed with 0.075 M phosphate buffer. Cells were
fixed in 0.5% aqueous osmium for two hours, followed
by a rinsing step with distilled water. Dehydration steps
followed and entailed increasing concentrations of etha-
nol (30%, 50%, 70%, 90%, 100%, 100%, 100%). Cells were
infiltrated with a series of increasing percentage of quetol
epoxy resin (30% for 30 minutes, 60% for 30 minutes and
100% quetol for four hours). Embedding of samples
followed and polymerization of the specimens was allowed
for 36 hours at 60°C. Ultra-thin sections were then pre-
pared with a microtome and mounted on a copper grid.
Samples were contrasted with 4% aqueous uranyl acetate
and Reynolds’ lead citrate. All chemical were obtained
from Merck (Darmstadt, Germany). Samples were viewed
with a JEM-210 °F field emission transmission electron
microscope (JEOL, Tokyo, Japan) at the Laboratory for
Microscopy and Microanalysis, University of Pretoria
(Pretoria, South Africa).
Confocal microscopy
Exponentially growing HeLa cells were seeded at 350 000
cells per well in 6-well plates on flame-sterilized cover slips.
After exposure, cells on cover slips were washed with pre-
warmed cytoskeletal buffer (CB) (60 mM PIPES, 27 mM,
10 mM EGTA and 4 mM magnesium sulphate with the
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pH adjusted to 7.0 with NaOH). Fixation of cells was done
with in pre-warmed 0.3% gluteraldehyde for 10 minutes at
37°C. This was followed by a wash step with warmed cyto-
skeletal buffer while agitating. Cell membranes were
permeablized using the permeabilization buffer (1% Triton
X-100 in CB) and agitated for 15 minutes. Cells were
washed once with CB buffer and then washed twice with
phosphate-buffered saline (PBS). Non-reacting aldehydes
were removed by treating samples three times with the
reducing agent (5 mg sodium borohydrite in 5 ml PBS).
Cover slips were incubated in a 10% normal host serum-
blocking buffer (10% FCS in PBS containing 0.05% Triton
X-100) for 60 minutes. Cover slips were incubated in a
primary mouse anti-tubulin alpha antibody (monoclonal
Antibody to Tubulin-alpha (clone DM1A), Imgenex, San
Diego, California, USA) cocktail (1:100 ratio antibody to
PBS-Triton wash buffer diluted with 50% blocking buffer)
for 90 minutes at 37°C in a humidity chamber. Cover slips
were washed at room temperature with PBS-Triton wash
buffer (PBS with 0.05% Triton X-100) with 1% FCS.
Samples were incubated while protected from light for
90 minutes at 37°C after adding secondary fluorescent
labelled (alexa Fluor® 488 dye) anti-mouse antibodies
(raised in donkey) (Invitrogen, Paisley, United Kingdom)
cocktail (1:125 as above) with a final concentration
2 mg/ml. Samples were washed with PBS-Triton wash
buffer with FCS. Nuclear staining was achieved by
incubating the cover slips in 50% DAPI (Thermo Fisher
Scientific Inc. Rockford, Illinois, USA) to equal volumes of
PBS for five to ten minutes while protected from light.
Counterstained cover slips were then washed with distilled
water, mounted with a glycerol-based mounting fluid and
cells were examined with a Zeiss LSM 510 Meta Confocal
Microscope (Zeiss, Jena, Germany) at the Laboratory for
Microscopy and Microanalysis, University of Pretoria,
Pretoria, South Africa. Cells were visualized using
immunofluorescent techniques in which green emissions
from the Alexa-488 probe were collected at 519 nm
(excited at 495 nm) and the blue DAPI at 461 nm
(excited at 358 nm).
Statistical analysis
Quantitative data were obtained from three independent
experiments. In addition, each of the independent exper-
iments was conducted in three replicates and is shown
as the mean ± standard deviation (SD). Quantitative data
were statistically analyzed for significance using the ana-
lysis of variance (ANOVA)-single factor model followed
by a two-tailed Student’s t-test. Means are presented in
bar charts, with T-bars referring to standard deviations.
P-values of less than 0.05 were regarded as statistically
significant and are indicated by an asterisk (*). For flow
cytometry, three independent experiments were done in
triplicate and data from at least 10 000 cells were
analyzed using Cyflogic version 1.2.1 software (Pertu
Therho, Turko, Finland). Flow cytometric measure-
ment of cell cycle progression and protocols involv-
ing FITC-labels and the aggresome kit are expressed
as relative fluorescence (a percentage of the value
measured for vehicle-treated negative control cells).
Morphological microscopy studies (qualitative data)
were repeated three times.
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